The Society for Cardiovascular Angiography and Interventions (SCAI) recently submitted comments to the Centers for Medicare & Medicaid Services’ (CMS) on the Medicare Coverage of Innovative Technology (MCIT) and Definition of “Reasonable and Necessary” Final Rule.
The comments noted that this past September, CMS proposed to stop the plan for the MCIT program which was scheduled to begin in December 2021. The letter went on to say that the rationale provided by CMS, that the breakthrough device may not have adequate evidence for both safety and efficacy in the Medicare population is understandable.
SCAI’s comments made clear, however, that SCAI believes that a coordinated and synergistic effort with CMS’s commitment to a parallel tract pathway may be adequate only because repeal appears to be inevitable.
To receive text messages about SCAI’s Government Relations activities, including grassroots messages to your Congressional Representatives, text “SCAI Advocacy” to 50457.
Data rates may apply. Limited to U.S. citizens and legal residents only.